参考文献/References:
［1］ Peron A， Northrup H. Tuberous sclerosis complex［J］. Am J Med Genet C Semin Med Genet， 2018， 178： 274- 277.
［2］ Gupta N， Finlay GA， Kotloff RM， et al. Lymphangioleiomyomatosis diagnosis and management： high- resolution chest computed tomography， transbronchial lung biopsy， and pleural disease management. An official American thoracic society/Japanese respiratory society clinical practice guideline［J］. Am J Respir Crit Care Med， 2017， 196： 1337- 1348.
［3］ Lam HC， Siroky BJ， Henske EP. Renal disease in tuberous sclerosis complex： pathogenesis and therapy［J］. Nat Rev Nephrol， 2018， 14： 704- 716.
［4］ Wang MX，Segaran N，Bhalla S，et al. Tuberous sclerosis： current update［J］. Radiographics， 2021， 41： 1992- 2010.
［5］ Saxton RA， Sabatini DM. mTOR signaling in growth， metabolism， and disease［J］. Cell， 2017， 168： 960- 976.
［6］ Dibble CC，Cantley LC. Regulation of mTORC1 by PI3K signaling［J］. Trends Cell Biol， 2015， 25： 545- 555.
［7］ Tyburczy ME，Dies KA，Glass J，et al. Mosaic and intronic mutations in TSC1/TSC2 explain the majority of TSC patients with no mutation identified by conventional testing［J］. PLoS Genet， 2015， 11： e1005637.
［8］ Northrup H，Krueger DA，International tuberous sclerosis complex consensus group. Tuberous sclerosis complex diagnostic criteria update： recommendations of the 2012 international tuberous sclerosis complex consensus conference［J］. Pediatr Neurol， 2013， 49： 243- 254.
［9］ Samuels JA. Treatment of renal angiomyolipoma and other hamartomas in patients with tuberous sclerosis complex［J］. Clin J Am Soc Nephrol， 2017， 12： 1196- 1202.
［10］ Oesterling JE，Fishman EK，Goldman SM，et al. The management of renal angiomyolipoma［J］. J Urol， 1986， 135： 1121- 1124.
［11］ Bhatt JR， Richard PO， Kim NS， et al. Natural history of renal angiomyolipoma（AML）： most patients with large AMLs＞4 cm can be offered active surveillance as an initial management strategy［J］. Eur Urol， 2016， 70： 85- 90.
［12］ Bardin F，Chevallier O，Bertaut A，et al. Selective arterial embo-lization of symptomatic and asymptomatic renal angiomyolipomas： a retrospective study of safety， outcomes and tumor size reduction［J］. Quant Imaging Med Surg， 2017， 7： 8- 23.
［13］ Yamakado KN，Nakagawa T. Renal angiomyolipoma： relationships between tumor size，aneurism formation，and rupture［J］. Radiology， 2002， 225： 78- 82.
［14］ Bissler JJ， Kingswood JC， Radzikowska E， et al. Everolimus for angiomyolipoma associated with tuberous sclerosis complex or sporadic lymphangioleiomyomatosis（EXIST- 2）： a multicentre， randomised， double- blind， placebo- controlled trial［J］. Lancet， 2013， 381： 817- 824.
［15］ Bissler JJ， Kingswood JC， Radzikowska E， et al. Everolimus for renal angiomyolipoma in patients with tuberous sclerosis complex or sporadic lymphangioleiomyomatosis： extension of a randomized controlled trial［J］. Nephrol Dial Transplant， 2016， 31： 111- 119.
［16］ Bissler JJ，Nonomura N，Budde K，et al. Angiomyolipoma rebound tumor growth after discontinuation of everolimus in patients with tuberous sclerosis complex or sporadic lymphangioleiomyomatosis［J］. PLoS One， 2018， 13： e0201005.
［17］ 刘 琦，侯毅斌，汤日杰，等． 选择性肾亚段动脉栓塞治疗肾错构瘤［J］． 介入放射学杂志， 2018， 27：477- 480．
［18］ Hocquelet A， Cornelis F， Le Bras Y， et al. Long- term results of preventive embolization of renal angiomyolipomas： evaluation of predictive factors of volume decrease［J］. Eur Radiol， 2014， 24： 1785- 1793.
［19］ Murray TE，Doyle F，Lee M. Transarterial embolization of angio-myolipoma： a systematic review［J］. J Urol， 2015， 194： 635- 639.
相似文献/References:
[1]刘 琦,侯毅斌,汤日杰,等.选择性肾亚段动脉栓塞治疗肾错构瘤 [J].介入放射学杂志,2018,27(05):477.
LIU Qi,HOU Yibin,TANG Rijie,et al.Selective renal segmental artery embolization for the treatment of renal angiomyolipoma[J].journal interventional radiology,2018,27(04):477.
[2]赵国峰,李 建,柏志斌,等.选择性动脉栓塞治疗孤立肾错构瘤6例 [J].介入放射学杂志,2016,(10):858.
ZHAO Guo- feng,LI Jian,BAI Zhi- bin,et al.Super- selective arterial embolization for the treatment of solitary renal hamartoma[J].journal interventional radiology,2016,(04):858.